250 related articles for article (PubMed ID: 18587545)
1. [Biological therapy for the treatment of rheumatic diseases].
Pierer M; Baerwald C
Internist (Berl); 2008 Aug; 49(8):938-46. PubMed ID: 18587545
[TBL] [Abstract][Full Text] [Related]
2. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
[TBL] [Abstract][Full Text] [Related]
3. New indications for treatment of chronic inflammation by TNF-alpha blockade.
Reimold AM
Am J Med Sci; 2003 Feb; 325(2):75-92. PubMed ID: 12589232
[TBL] [Abstract][Full Text] [Related]
4. [Biologicals in the treatment of rheumatic diseases].
Scherer HU; Burmester GR
Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
[No Abstract] [Full Text] [Related]
5. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
[TBL] [Abstract][Full Text] [Related]
6. Biologics in Inflammatory and Immunomediated Arthritis.
Luchetti MM; Benfaremo D; Gabrielli A
Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
[TBL] [Abstract][Full Text] [Related]
7. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Kalliolias GD; Liossis SN
Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
[TBL] [Abstract][Full Text] [Related]
8. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
9. [Biological treatment of rare inflammatory rheumatic diseases].
Baslund B
Ugeskr Laeger; 2008 Jun; 170(24):2150-2. PubMed ID: 18565301
[TBL] [Abstract][Full Text] [Related]
10. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
[TBL] [Abstract][Full Text] [Related]
11. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
12. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Sieper J; Emery P; Keystone EC; Schiff MH; Mease P; van Riel PL; Fleischmann R; Weisman MH; Weinblatt ME
Ann Rheum Dis; 2007 Nov; 66 Suppl 3(Suppl 3):iii2-22. PubMed ID: 17934088
[No Abstract] [Full Text] [Related]
13. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
Kakkassery V; Mergler S; Pleyer U
Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
[TBL] [Abstract][Full Text] [Related]
14. [Indications and efficacy of biologics in inflammatory arthritis].
Combe B
Bull Acad Natl Med; 2012 Oct; 196(7):1279-92; discussion 1293. PubMed ID: 23815014
[TBL] [Abstract][Full Text] [Related]
15. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.
Wiedmann MW; Mössner J; Baerwald C; Pierer M
Endocr Metab Immune Disord Drug Targets; 2009 Sep; 9(3):295-314. PubMed ID: 19594416
[TBL] [Abstract][Full Text] [Related]
16. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
17. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
[TBL] [Abstract][Full Text] [Related]
19. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
Sfikakis PP
Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic use of "biologics" in inflammatory joint and spinal diseases].
Seitz M
Ther Umsch; 2002 Oct; 59(10):535-43. PubMed ID: 12428439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
